Shares of Cepheid (NASDAQ:CPHD) have been given an average rating of “Hold” by the twenty research firms that are covering the stock. Fifteen analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $42.73.

Several equities research analysts have weighed in on CPHD shares. Jefferies Group upped their target price on Cepheid from $28.00 to $34.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Cowen and Company cut Cepheid from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 7th. Barclays PLC upped their target price on Cepheid from $36.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 7th. Robert W. Baird upped their target price on Cepheid from $44.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 7th. Finally, Canaccord Genuity restated a “hold” rating on shares of Cepheid in a research note on Tuesday.

Hedge funds have recently modified their holdings of the stock. Societe Generale purchased a new stake in shares of Cepheid during the second quarter valued at approximately $114,000. First Mercantile Trust Co. increased its stake in shares of Cepheid by 6.6% in the second quarter. First Mercantile Trust Co. now owns 4,020 shares of the company’s stock valued at $124,000 after buying an additional 250 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Cepheid by 13.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,486 shares of the company’s stock valued at $131,000 after buying an additional 299 shares during the last quarter. Globeflex Capital L P acquired a new position in shares of Cepheid during the second quarter valued at $145,000. Finally, Advisor Group Inc. acquired a new position in shares of Cepheid during the second quarter valued at $145,000. Institutional investors own 95.75% of the company’s stock.

Shares of Cepheid (NASDAQ:CPHD) opened at 52.95 on Friday. Cepheid has a 52 week low of $25.09 and a 52 week high of $53.91. The company’s 50 day moving average price is $52.75 and its 200-day moving average price is $38.36. The firm’s market capitalization is $3.89 billion.

TRADEMARK VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/23/cepheid-cphd-receives-41-83-consensus-target-price-from-brokerages.html.

Cepheid Company Profile

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

5 Day Chart for NASDAQ:CPHD

Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.